Dar? Bioscience, Inc. - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
DARE Nasdaq 2840 darebioscience.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Dar? Bioscience, Inc.

Daré Bioscience to Present at Stifel’s 2026 Healthcare Conference - Nov 4th, 2026 7:05 am
Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum - Oct 30th, 2026 6:32 am
Daré Bioscience Addresses New National Focus on Women’s Health in Virtual Investor “What This Means” Discussion - Oct 28th, 2026 6:47 am
Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly - Oct 26th, 2026 6:32 am
Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer - Oct 19th, 2026 6:56 am
Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities - Oct 13th, 2026 7:15 am
Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting - Oct 8th, 2026 7:15 am
Dare Bioscience stock rises after receiving HPV treatment patent - Sep 28th, 2026 8:32 am
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection - Sep 28th, 2026 6:20 am
Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil - Sep 14th, 2026 6:50 am
Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand - Sep 11th, 2026 4:55 am
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth - Aug 31st, 2026 6:44 am
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series - Aug 27th, 2026 7:01 am
Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society - Aug 26th, 2026 6:45 am
Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment - Aug 25th, 2026 6:55 am
Daré Bioscience (DARE) Q2 2026 Earnings Call Transcript - Aug 20th, 2026 2:55 pm
DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List - Aug 18th, 2026 7:02 am
Dare Bioscience Inc (DARE) (Q2 2026) Earnings Call Highlights: Commercial Launch Milestones and ... - Aug 17th, 2026 2:34 pm
Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Aug 14th, 2026 10:45 am
Daré Bioscience, Inc. Q2 2026 Earnings Call Summary - Aug 14th, 2026 6:30 am